Atlantic Health System

COVID-19 Clinical Research Study Underway at Atlantic Health System, Including Immune Response Study

With a large number of COVID-19 patients in NJ, many are enrolling in dynamic, new COVID Research Program clinical study
4-Jun-2020 5:45 AM EDT, by Atlantic Health System

Newswise — As the world clamors for effective treatments and a vaccine against coronavirus 19 (COVID-19), Atlantic Health System is calling on its expertise and national reputation for conducting leading edge clinical trials in oncology, neuroscience, cardiology and other fields. The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Internationally known academic medical centers from other parts of the country are partnering with Atlantic Health System to increase access to innovative trials. 

“Almost overnight, we have built a robust COVID-19 clinical research study,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care. “The caliber of our research program is a result of the hard work and dedication of our physicians, staff, research team, external research partnerships and our reputation,” added Dr. Whitman. 

Atlantic Health System Offers Immune Response Study

Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.

The purpose of this study is to understand how immune cells mount an immune response to COVID-19. This knowledge will be used in an effort to develop new treatments, vaccines, or diagnostics against COVID-19. Patients who have recently recovered from a COVID-19 infection have immune cells with the ability to recognize and attack the virus, but it is not clear how immune cells recognize COVID-19. TScan is leveraging its proprietary discovery platform to identify the precise epitopes recognized by T cells in COVID-19 recovered patients.

“Recovered patients, who choose to volunteer for the TScan clinical research study, will have a one-time blood sample collected so researchers can study how the patient’s T cells recognize and control the virus,” said Principal Investigator Angela Alistar, MD, medical director of the Breakthrough Treatment Center, and of GI Medical Oncology at Morristown Medical Center. “The goal is to use this information to design effective vaccines that will generate appropriate T cell responses in people who have not yet been infected with the virus.”

This research could be used to generate a vaccine which should provide individuals with robust immunity against any potential future COVID-19 infection.

The COVID Research Program 

Atlantic Center for Research and Atlantic Health System Cancer Care recruited experts in research from the oncology, infectious diseases and research departments at Morristown and Overlook medical centers to form and conduct new studies focused on COVID-19. Once the pandemic hit, the group volunteered to focus on getting a world-class COVID Research Program off the ground. Other departments soon joined in, including cardiac research, cystic fibrosis research and radiation therapy. 

“The COVID Research Team is fast-tracking a broad range of exciting research studies and doing whatever they can to improve the quality of care for patients,” said Jan Schwarz-Miller, MD, MPH, Chief Medical and Academic Officer, Atlantic Health System.

“Our research team has stepped forward, working long hours to make this happen and rapidly enrolling many of the region’s patients in our clinical trials.” 

Among others, the physician investigators include infectious disease specialists, Jason A. Kessler, MD, from Morristown Medical Center, and Robert J. Roland, DO, from Overlook Medical Center; pulmonary and critical care physicians Lewis Rubinson, MD, PhD and Stanley Fiel, MD from Morristown Medical Center; John Halperin, MD, medical director, Atlantic Health System Neuroscience; Elliot Rosenstein, MD, medical director, Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center; and several members of Atlantic Medical Group Oncology: Charles M Farber, MD, PhD, medical director of Oncology Research Network Development for Atlantic Health System; Mohamad Cherry, MD, medical director of Hematology, Morristown Medical Center; Sophie Morse, MD, oncology, Overlook Medical Center; and Dr. Alistar and Dr. Whitman. 

To learn more about COVID-19 clinical trials at Atlantic Health System, visit www.atlantichealth.org/research.

 

About Atlantic Health System 

Atlantic Health System has a long-standing tradition of providing exceptional patient outcomes and experiences. Home to seven award-winning hospitals including Morristown Medical Center, the number one hospital in NJ according to U.S. News & World Report, Castle Connolly and Newsweek’s World’s Best Hospitals, the system has been ranked first in New Jersey in consumer preference by Monigle and first among health systems in New Jersey as a “best workplace” by both Modern Healthcare and Fortune Magazine. 

Many of the system’s programs have received national accolades and designations, including Morristown Medical Center’s Cardiology and Heart Surgery program ranked among the top 30 in the nation by U.S. News and World Report; Morristown Medical Center’s Orthopedics program ranked among the top 35 in the nation by U.S. News and World Report and Atlantic Health System’s Cancer Care program, New Jersey’s first and only National Cancer Institute National Community Oncology Research Program. Additionally, Atlantic Health System Neuroscience at Overlook Medical Center, working with Atlantic Mobile Health, was the first in the nation to deploy and use portable Telestroke technology in ambulances for routine pre-hospital assessment of stroke patients. 

Powered by a passionate workforce of 17,000 team members and 4,800 affiliated physicians dedicated to building healthier communities, Atlantic Health System serves more than half of the state of New Jersey, including 11 counties and 4.9 million people. The system provides care for the full continuum of health needs across a wide array of settings, including Atlantic Medical Group, one of the largest multi-specialty practices in New Jersey with more than 1,000 physicians and providers, 12 urgent care centers, Atlantic Rehabilitation Institute, Atlantic Home Care and Hospice and Atlantic Anywhere’s Virtual Visits. Facilitating connections between these services on both land and air is the transportation fleet of Atlantic Mobile Health. 

With a clear sense of purpose and an unparalleled culture, Atlantic Health System attracts top leaders in the field of health care, from CEO Brian Gragnolati, who was Chairman of the American Hospital Association in 2019, to the numerous team members who serve as leaders across national clinical associations and research entities.




Filters close

Showing results

110 of 2767
Released: 3-Aug-2020 9:00 AM EDT
Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19
Neutrolis

Novel Chromatinase™ platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19

Released: 3-Aug-2020 8:55 AM EDT
American College of Radiology to Provide Image Coordination for National COVID-19 Observational Study
American College of Radiology (ACR)

The American College of Radiology® (ACR®) Center for Research and Innovation™ (CRI) will serve as the imaging coordination center for the multicenter COVID-19 Observational Study (CORAL) led by Dr. Catherine "Terri" L. Hough of the Oregon Health & Science University. The CORAL Study is part of the Prevention & Early Treatment of Acute Lung Injury (PETAL) Network, a consortium of academic and affiliated hospitals across the United States – funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health – to conduct clinical trials in patients with or at risk for critical illness, including acute respiratory distress syndrome.

Released: 3-Aug-2020 8:35 AM EDT
Evaluating the effectiveness of travel bans
International Institute for Applied Systems Analysis

A new study sheds light on how COVID-19 spreads regionally and between countries, as well as on how effective governmental measures to curb the spread of the pandemic have been to date.

Newswise: Engineers developing no-touch, mail-in, fast-scan test for COVID-19, other outbreaks
Released: 3-Aug-2020 8:00 AM EDT
Engineers developing no-touch, mail-in, fast-scan test for COVID-19, other outbreaks
Iowa State University

Engineers are developing a no-touch, mail-in, fast-scan diagnostic sensing system that could be used to quickly test for COVID-19 or other outbreaks. The system would also produce a real-time outbreak map with demographic details.

Newswise: Atrium Health Tele-ICU Evolves to Meet COVID-19 Challenges
30-Jul-2020 1:55 PM EDT
Atrium Health Tele-ICU Evolves to Meet COVID-19 Challenges
American Association of Critical-Care Nurses (AACN)

Atrium Health’s tele-ICU quickly adjusted its patient-centered focus to include supporting and protecting bedside nurses caring for patients in isolation, as part of the system’s planning and preparations for the pandemic.

Released: 31-Jul-2020 5:05 PM EDT
Looking up to the Joneses: Consequences of the perceptions of white wealth
Society for Personality and Social Psychology

Before the era of COVID-19, research suggested that premature deaths among white Americans were rising. Even before the era of COVID-19, these findings were surprising.

Newswise: 238996_web.jpg
Released: 31-Jul-2020 4:55 PM EDT
Pooling strategy in the wake of the COVID-19 pandemic: A solution for mass population screening of SARS-CoV-2
Elsevier

In a report in the Journal of Molecular Diagnostics, published by Elsevier, researchers at Augusta University and PerkinElmer Genomics describe a cheaper, rapid, and accurate pooling strategy for the RT-PCR-based detection of SARS-CoV-2 in clinical samples.

Released: 31-Jul-2020 4:40 PM EDT
No racial disparities seen in response to remdesivir treatment of COVID-19
University of Chicago Medical Center

A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 3-Aug-2020 11:00 AM EDT Released to reporters: 31-Jul-2020 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 31-Jul-2020 3:50 PM EDT
SARS-CoV-2 screening strategies for safe reopening of college campuses
JAMA - Journal of the American Medical Association

What The Study Did: This study defines the screening performance standards for SARS-CoV-2 tests that would permit the safe return of students to U.S. residential college campuses this fall. Authors: A. David Paltiel, Ph.D., of the Yale School of Public Health in New Haven, Connecticut, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2020.16818) Editor's Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. ### Media advisory: The full study and commentary are linked to this news release. Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/1


Showing results

110 of 2767

close
1.00519